| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/19/2012 | US20120015991 Polycyclic antagonists of lysophosphatidic acid receptors |
| 01/19/2012 | US20120015990 Taspase1 inhibitors and their uses |
| 01/19/2012 | US20120015989 Linked myc-max small molecule inhibitors |
| 01/19/2012 | US20120015988 Sulfone Compounds Which Modulate The CB2 Receptor |
| 01/19/2012 | US20120015985 Methods of Administering Pirfenidone Therapy |
| 01/19/2012 | US20120015979 Compounds for Modulating TRPV3 Function |
| 01/19/2012 | US20120015976 Autotaxin inhibitors |
| 01/19/2012 | US20120015974 Imidazopyridine inhibitors of iap |
| 01/19/2012 | US20120015973 Mek mutations conferring resistance to mek inhibitors |
| 01/19/2012 | US20120015969 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 01/19/2012 | US20120015968 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper-and sterile alpha motif-containing kinase (zak) |
| 01/19/2012 | US20120015966 Ppar active compounds |
| 01/19/2012 | US20120015965 Pharmaceutical composition comprising n-[3-chloro-4-[(3-fluorophenyl)methoxy] phenyl]-6-[5[[[2-(methylsulfonyl) ethyl]amino]methyl]-2-furyl]-4- quinazolinamine |
| 01/19/2012 | US20120015964 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| 01/19/2012 | US20120015963 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| 01/19/2012 | US20120015960 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient |
| 01/19/2012 | US20120015959 Heterocyclic compounds as autotaxin inhibitors |
| 01/19/2012 | US20120015956 Deuterium-enriched dasatinib |
| 01/19/2012 | US20120015955 F, G, H, I and K Crystal Forms of Imatinib Mesylate |
| 01/19/2012 | US20120015952 Inhibitors of NF-KB |
| 01/19/2012 | US20120015950 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof |
| 01/19/2012 | US20120015943 Substituted hydroxamic acids and uses thereof |
| 01/19/2012 | US20120015942 Substituted hydroxamic acids and uses thereof |
| 01/19/2012 | US20120015940 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 01/19/2012 | US20120015937 Kinase Inhibitors And Their Uses |
| 01/19/2012 | US20120015935 Substituted Tetrahydropyrazolo-Pyrido-Azepine Compounds |
| 01/19/2012 | US20120015934 Cyclopamine lactam analogs and methods of use thereof |
| 01/19/2012 | US20120015933 Spirocyclic nitriles as protease inhibitors |
| 01/19/2012 | US20120015931 Purine compounds selective for pi3k p110 delta, and methods of use |
| 01/19/2012 | US20120015927 Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6--4-pyrimidinyl]-1-azetidinesulfonamide |
| 01/19/2012 | US20120015926 Compounds for the treatment of inflammatory disorders |
| 01/19/2012 | US20120015920 Heterobicyclic metalloprotease inhibitors |
| 01/19/2012 | US20120015919 Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists |
| 01/19/2012 | US20120015914 Formulations of 14-epi-analogues of vitamin d |
| 01/19/2012 | US20120015913 Formulations of 14-EPI-Analogues of Vitamin D |
| 01/19/2012 | US20120015912 Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| 01/19/2012 | US20120015908 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 01/19/2012 | US20120015907 Furopyridine compounds and uses thereof |
| 01/19/2012 | US20120015906 Uses of bortezomib in predicting survival in multiple myeloma patients |
| 01/19/2012 | US20120015900 Cobalamin Taxane Bioconjugates |
| 01/19/2012 | US20120015899 Modified plant virus particles and uses therefor |
| 01/19/2012 | US20120015889 Method for the administration of ligands, agonists of ligands of the tnf family with reduced toxicity |
| 01/19/2012 | US20120015888 T cell receptors and related materials and methods of use |
| 01/19/2012 | US20120015887 Synthetic peptide and uses thereof |
| 01/19/2012 | US20120015871 Complement receptor 2 targeted complement modulators |
| 01/19/2012 | US20120015868 Metastin derivatives and use thereof |
| 01/19/2012 | US20120015402 Method of Proliferating Plasma Cells |
| 01/19/2012 | US20120015056 Composition comprising extracts or fractions of specific plants, use thereof and process for preparing the extracts |
| 01/19/2012 | US20120015050 Methods and materials for assessing loss of heterozygosity |
| 01/19/2012 | US20120015049 Microrna biomarker in cancer |
| 01/19/2012 | US20120015027 F, G, H, I and K Crystal Forms of Imatinib Mesylate |
| 01/19/2012 | US20120015026 Pharmaceutical composition containing a drug and sirna |
| 01/19/2012 | US20120015025 Cholestanol derivative for combined use |
| 01/19/2012 | US20120015023 Treatment of tumors prostate with arsonoliposomes |
| 01/19/2012 | US20120015005 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| 01/19/2012 | US20120014997 Aryl sulfonamides |
| 01/19/2012 | US20120014996 Method of diagnosing bladder cancer |
| 01/19/2012 | US20120014990 Vaccination methods |
| 01/19/2012 | US20120014984 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 01/19/2012 | US20120014977 NOVEL ALTERNATIVE SPLICING VARIANT OF OATP1B3 mRNA |
| 01/19/2012 | US20120014971 Interleukin-1 Alpha Antibodies and Methods of Use |
| 01/19/2012 | US20120014969 ErbB3 ANTIBODIES |
| 01/19/2012 | US20120014965 Compositions and methods of treating tumors |
| 01/19/2012 | US20120014961 Antibodies that inhibit tslp activity |
| 01/19/2012 | US20120014958 Stable and soluble antibodies inhibiting vegf |
| 01/19/2012 | US20120014957 Dual variable domain immunoglobulins and uses thereof |
| 01/19/2012 | US20120014954 Sparc binding scfvs |
| 01/19/2012 | US20120014952 Complement receptor 2 targeted complement modulators |
| 01/19/2012 | US20120014950 Antibodies That Specifically Bind to DR3 |
| 01/19/2012 | US20120014948 Genetic products differentially expressed in tumors and use thereof |
| 01/19/2012 | US20120014947 Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system |
| 01/19/2012 | US20120014943 Optimized Anti-CD30 Antibodies |
| 01/19/2012 | US20120014942 Method for the diagnosis and prognosis of malignant diseases |
| 01/19/2012 | US20120014941 Anti-bv8 antibodies and uses thereof |
| 01/19/2012 | US20120014937 Human Beta-Adrenergic receptor kinase polypeptide and methods |
| 01/19/2012 | US20120014927 Methods and kits for determining predisposition to cancer |
| 01/19/2012 | US20120014911 Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| 01/19/2012 | US20120014904 Vascular delivery systems |
| 01/19/2012 | US20120014877 COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS |
| 01/19/2012 | US20120014876 Antagonistic peptides for frizzled-1 and frizzled-2 |
| 01/19/2012 | US20120014875 Nucleic acid aptamers |
| 01/19/2012 | US20120014873 Peptides whose uptake by cells is controllable |
| 01/19/2012 | US20120014872 Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers |
| 01/19/2012 | US20120014871 Ovarian Cancer Methylome |
| 01/19/2012 | US20120014869 Muc18 targeting peptides |
| 01/19/2012 | US20120012123 Compositions, articles and methods for preventing or reducing tobacco-associated damage |
| 01/19/2012 | CA2841866A1 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |
| 01/19/2012 | CA2805643A1 Targeted nanoparticles for cancer and other disorders |
| 01/19/2012 | CA2805608A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 01/19/2012 | CA2805590A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 01/19/2012 | CA2805338A1 Peptide for use in the treatment of breast cancer and/or bone metastases |
| 01/19/2012 | CA2805148A1 Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors |
| 01/19/2012 | CA2805136A1 New compounds for treating cancer and other diseases |
| 01/19/2012 | CA2805015A1 Bicyclic pyrimidines |
| 01/19/2012 | CA2804753A1 Anti-angiogenic agent and methods of using such agent |
| 01/19/2012 | CA2804278A1 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| 01/19/2012 | CA2804185A1 Multifunctional antibody conjugates |
| 01/19/2012 | CA2803675A1 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 01/19/2012 | CA2802808A1 Purine compounds selective for pi3k p110 delta, and methods of use |
| 01/19/2012 | CA2799036A1 Superior efficacy of cd37 antibodies in cll blood samples |